Tricida, Inc.

Report azionario OTCPK:TCDA.Q

Capitalizzazione di mercato: US$580.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Tricida Gestione

Criteri Gestione verificati 3/4

Tricida Il CEO è Gerrit Klaerner, nominato in Aug2013, e ha un mandato di 9.83 anni. la retribuzione annua totale è $ 4.68M, composta da 12.8% di stipendio e 87.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.68% delle azioni della società, per un valore di $ 3.93. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4 anni e 9.5 anni.

Informazioni chiave

Gerrit Klaerner

Amministratore delegato

US$4.7m

Compenso totale

Percentuale dello stipendio del CEO12.83%
Mandato del CEO9.8yrs
Proprietà del CEO0.7%
Durata media del management4yrs
Durata media del Consiglio di amministrazione9.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Oct 19

Tricida enters $125M debt facility

Tricida (NASDAQ:TCDA) gets into a debt facility of $125M with Hercules Capital, provider of customized debt financing for companies in the life sciences and technology-related markets. Of the $125M, $100M will be available for drawdown at Tricida’s option subject to the achievement of certain milestones. Under the terms of the debt facility, $25M will be available for drawdown until December 31, 2022, subject to the announcement of positive data from the VALOR-CKD trial.  An additional $25M will be available for drawdown until the earlier of ten business days following the filing of the NDA for veverimer and September 15, 2023. An additional $50M will be available for drawdown until the earlier of ten business days following the FDA approval of veverimer and February 15, 2024. The loans bear interest at a floating per annum interest rate equal to the greater of either 8.75% or the lesser of 8.75% plus the prime rate as reported in The Wall Street Journal minus 6.25% and 10.25%.
Seeking Alpha • Sep 21

Tricida: Important Binary Event Coming Up

Summary TCDA has a major binary event next month. Data from VALOR may turn out well given the logic behind early trial termination, prior data and so on. There could be some quick upside in the next 30 odd days. Tricida (TCDA) has been doing wonderfully lately, over the last 12 months, but it is down considerably from its PDUFA highs. That was from two years ago, when I used to cover the stock. I recall buying some TCDA, making good money, and then losing some money on the shares I held on to, because their lead asset veverimer was handed a CRL. The stock is up these days not because the CRL was resolved, but because of a number of other small and large things. Let's first discuss the CRL, though. Then we will see what has been responsible for the stock’s sudden buoyancy. Veverimer is targeting metabolic acidosis in CKD or chronic kidney disease patients. In an earlier trial, after 12 weeks of treatment, TRC101 or veverimer was able to increase blood bicarbonate level of at least 4 milliequivalents per liter (mEq/L) or achieved a blood bicarbonate level in the normal range of 22 to 29 mEq/L in 59.2% patients, compared with 22.5% of them in the placebo group (p< 0.0001). However, one of veverimer’s major problem is the standardly used therapy for this indication, which you can buy in a bottle from a grocery store for a few bucks. This is bicarbonate of soda, and while there have been no industry-sponsored trials for obvious reasons, it has long been used by doctors to treat metabolic acidosis. Its problem is that too much sodium content in the blood can cause heart diseases, which is where veverimer has a great deal of utility with its completely different mechanism of action. However, the FDA was not convinced, and it issued a CRL, asking for, among other things: Additional data regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate. Whether the demonstrated effect size would be reasonably likely to predict clinical benefit. I discussed all this in an earlier article from two years ago. A summary of the CRL from the company management was here: “According to the CRL, the FDA is seeking additional data beyond the TRCA-301 and TRCA-301E trials regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate and the applicability of the treatment effect to the U.S. population. FDA also expressed concern as to whether the demonstrated effect size would be reasonably likely to predict clinical benefit,” Tricida said. This was an accelerated approval, and the company was already conducting VALOR-CKD at that time as a confirmatory trial. After the CRL, they said that interim data from this trial could be used to provide the data required by the FDA. This trial was supposed to enroll ~1500 patients and topline in 2023-24. In May, the company did an “administrative stop” to this trial after enrolling 1480 patients last year, and after 237 patients reached a primary endpoint event — end-stage renal disease, renal death, or greater than or equal to 40% reduction in eGFR or estimated glomerular filtration rate — in the renal outcomes study. This was done to conserve their cash reserve, which will be near depleted this quarter. Moreover, the FDA seems to have agreed that this may work. As Phil Nadeau at Cowen explained: Assuming a true hazard ratio ((HR)) of 0.70, the trial would be 78% powered at 250 events. Switching from power to observed HR, VALOR-CKD could be successful at 250 events if the observed HR is 0.78. There is only a modest increase to 0.79 observed HR should 300 events be in the final analysis. This calculation on the observed HR required for significance is based on 300 simulations on trial outcomes.
Articolo di analisi • Sep 14

Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)

Today we will run through one way of estimating the intrinsic value of Tricida, Inc. ( NASDAQ:TCDA ) by estimating the...
Articolo di analisi • Dec 14

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

Investors who take an interest in Tricida, Inc. ( NASDAQ:TCDA ) should definitely note that the CFO & Executive VP...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Gerrit Klaerner rispetto agli utili di Tricida?
DataCompenso totaleStipendioUtili della società
Sep 30 2022n/an/a

-US$134m

Jun 30 2022n/an/a

-US$148m

Mar 31 2022n/an/a

-US$153m

Dec 31 2021US$5mUS$600k

-US$177m

Sep 30 2021n/an/a

-US$181m

Jun 30 2021n/an/a

-US$219m

Mar 31 2021n/an/a

-US$244m

Dec 31 2020US$9mUS$598k

-US$265m

Sep 30 2020n/an/a

-US$268m

Jun 30 2020n/an/a

-US$235m

Mar 31 2020n/an/a

-US$213m

Dec 31 2019US$10mUS$584k

-US$177m

Sep 30 2019n/an/a

-US$146m

Jun 30 2019n/an/a

-US$131m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$1mUS$503k

-US$103m

Sep 30 2018n/an/a

-US$96m

Jun 30 2018n/an/a

-US$77m

Mar 31 2018n/an/a

-US$60m

Dec 31 2017US$821kUS$425k

-US$41m

Compensazione vs Mercato: La retribuzione totale di Gerrit ($USD 4.68M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 655.15K ).

Compensazione vs guadagni: La retribuzione di Gerrit è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Gerrit Klaerner (51 yo)

9.8yrs
Mandato
US$4,676,490
Compensazione

Dr. Gerrit Klaerner, Ph.D. Founded Tricida, Inc.and has been its Chief Executive Officer and President since August 2013 and has been its an Executive Director since July 2013. Dr. Klaerner was the Founder...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Gerrit Klaerner
Founder9.8yrsUS$4.68m0.68%
$ 3.9
Geoffrey Parker
COO, CFO & Executive VP6.2yrsUS$2.51m0.72%
$ 4.2
Robert McKague
Executive VP3.3yrsUS$2.43m0.031%
$ 0.2
Dawn Parsell
Executive Vice President of Clinical Development4.8yrsUS$2.77m0.0060%
$ 0.03
Annie Yoshiyama
VP of Finance & Chief Accounting Officer2.5yrsNessun datoNessun dato
Jackie Cossmon
Vice President of Investor Relations & Communicationsno dataNessun datoNessun dato
Edward Hejlek
Executive Vice President of Intellectual Property3.3yrsUS$2.10mNessun dato
4.0yrs
Durata media
58yo
Età media

Gestione esperta: Il team dirigenziale di TCDA.Q è considerato esperto (durata media dell'incarico 4 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Gerrit Klaerner
Founder9.9yrsUS$4.68m0.68%
$ 3.9
Kathryn Falberg
Independent Non-Employee Director5.1yrsUS$329.00k0.074%
$ 0.4
Klaus Veitinger
Independent Chairman of the Board9.3yrsUS$379.00k0.20%
$ 1.1
David Hirsch
Independent Non-Employee Director6.9yrsUS$326.50k0.019%
$ 0.1
Robert Alpern
Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board9.7yrsUS$314.00kNessun dato
John Fordtran
Member of Scientific & Clinical Advisory Boardno dataNessun datoNessun dato
David Bushinsky
Member of Scientific & Clinical Advisory Boardno dataNessun datoNessun dato
Craig Hawker
Member of Scientific & Clinical Advisory Boardno dataNessun datoNessun dato
Sandra Coufal
Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board9.9yrsUS$316.50k0.15%
$ 0.9
Navdeep Tangri
Member of Scientific & Clinical Advisory Boardno dataNessun datoNessun dato
Thomas Hostetter
Member of Scientific & Clinical Advisory Boardno dataNessun datoNessun dato
Bertram Pitt
Member of Scientific and Clinical Advisory Boardno dataNessun datoNessun dato
9.5yrs
Durata media
60yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TCDA.Q sono considerati esperti (durata media dell'incarico 9.5 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2023/06/13 08:08
Prezzo dell'azione a fine giornata2023/06/13 00:00
Utili2022/09/30
Utili annuali2021/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Tricida, Inc. è coperta da 3 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Dana FlandersGoldman Sachs
Jessica FyeJ.P. Morgan
Philip NadeauTD Cowen